Literature DB >> 1459004

Intercalation of anthracyclines into living cell DNA analyzed by flow cytometry.

F Belloc1, F Lacombe, P Dumain, F Lopez, P Bernard, M R Boisseau, J Reifers.   

Abstract

Anthracyclines (ANT) are used in the treatment of leukemia and other cancers. These drugs have been shown to intercalate between the strands of DNA. In the present study, we show that the amount of ANT intercalated into DNA can be determined by measuring the fluorescence resonance energy transfer (FRET) between Hoechst 33342 (H33342) and ANT bound to DNA. The transfer efficiency was found to depend on the amount of disposable ANT but was independent of the amount of H33342 bound to DNA over a wide range of H33342 concentrations. The method was adapted for flow cytometric measurement of FRET in whole living cells and was used to evaluate the degree of intercalation of daunorubicin (DAU) and idarubicine (IDA) into DAU-sensitive and DAU-resistant leukemic cell lines. ANT intercalation into DNA was affected by factors which modify the intracytoplasmic concentration of ANT, and it was shown that the action of ANT and the resistance to ANT could not be attributed solely to the intercalative effect of the drugs. The method has advantages over previously described methods and represents a useful complementary tool in studies on the mode of action of ANT and the mechanisms of chemoresistance.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1459004     DOI: 10.1002/cyto.990130811

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  8 in total

1.  Cytotoxicity of anthracyclines: correlation with cellular uptake, intracellular distribution and DNA binding.

Authors:  F Gieseler; H Biersack; T Brieden; J Manderscheid; V Nüssler
Journal:  Ann Hematol       Date:  1994       Impact factor: 3.673

2.  Simultaneous delivery of chemotherapeutic and thermal-optical agents to cancer cells by a polymeric (PLGA) nanocarrier: an in vitro study.

Authors:  Yuan Tang; Tingjun Lei; Romila Manchanda; Abhignyan Nagesetti; Alicia Fernandez-Fernandez; Supriya Srinivasan; Anthony J McGoron
Journal:  Pharm Res       Date:  2010-08-06       Impact factor: 4.200

3.  Promoter-specific inhibition of transcription by daunorubicin in Saccharomyces cerevisiae.

Authors:  Silvia Marín; Sylvia Mansilla; Natàlia García-Reyero; Marta Rojas; José Portugal; Benjamin Piña
Journal:  Biochem J       Date:  2002-11-15       Impact factor: 3.857

4.  Comparing cellular uptake and cytotoxicity of targeted drug carriers in cancer cell lines with different drug resistance mechanisms.

Authors:  Tingjun Lei; Supriya Srinivasan; Yuan Tang; Romila Manchanda; Abhignyan Nagesetti; Alicia Fernandez-Fernandez; Anthony J McGoron
Journal:  Nanomedicine       Date:  2010-11-19       Impact factor: 5.307

Review 5.  Liposomal daunorubicin as treatment for Kaposi's sarcoma.

Authors:  Christin E Petre; Dirk P Dittmer
Journal:  Int J Nanomedicine       Date:  2007

6.  Efficient lytic induction of Kaposi's sarcoma-associated herpesvirus (KSHV) by the anthracyclines.

Authors:  Hyunju Kang; Jaehyung Song; Kwangman Choi; Hyeongki Kim; Miri Choi; So-Young Lee; Chonsaeng Kim; Sang Jun Lee; Moon Jung Song; Hyojeung Kang; Sung Hoon Back; Sang-Bae Han; Sungchan Cho
Journal:  Oncotarget       Date:  2014-09-30

7.  Interactions of Cisplatin and Daunorubicin at the Chromatin Level.

Authors:  Erfaneh Firouzi Niaki; Thibaut Van Acker; László Imre; Péter Nánási; Szabolcs Tarapcsák; Zsolt Bacsó; Frank Vanhaecke; Gábor Szabó
Journal:  Sci Rep       Date:  2020-01-24       Impact factor: 4.379

8.  Selective inhibition of yeast regulons by daunorubicin: a transcriptome-wide analysis.

Authors:  Marta Rojas; Marta Casado; José Portugal; Benjamin Piña
Journal:  BMC Genomics       Date:  2008-07-30       Impact factor: 3.969

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.